Clinical Trial Detail

NCT ID NCT03465891
Title Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

follicular lymphoma

Therapies

Atezolizumab

Age Groups: adult senior

No variant requirements are available.